Evidence map›Paper›PMID 40988928›Full record

ReviewFrontiers in genetics2025

Mechanisms and recent advances in non-coding RNAs and RNA modifications in antiplatelet drug resistance.

Ping Ni, Kejie Chen, Jing Xiang, Haifeng Shao, Xiaoling Chen, Qiao Chen, Lingling Wang, Junli Hao, Xinyi Huang, Qing Cao and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ping NiSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Kejie ChenSchool of Public Health, Chengdu Medical College, Chengdu, China.
Jing XiangSchool of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Haifeng ShaoSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine Chengdu, Chengdu, China.
Xiaoling ChenSchool of Clinical Medicine, Southwest Medical University, Luzhou, China.
Qiao ChenSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine Chengdu, Chengdu, China.
Lingling WangSchool of Comprehensive Health Management, Xihua University, Chengdu, China.
Junli HaoSchool of Biomedical Sciences and Technology, Chengdu Medical College, Chengdu, China.
Xinyi HuangSchool of Biomedical Sciences and Technology, Chengdu Medical College, Chengdu, China.
Qing CaoSchool of Clinical Medicine, Southwest Medical University, Luzhou, China.
Yali YangSchool of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine Chengdu, Chengdu, China.
Quandan TanDepartment of Neurology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Jie YangDepartment of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Suping LiDepartment of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high incidence and mortality rates of cardiovascular and cerebrovascular diseases make them a significant global health challenge. Antiplatelet drugs play a central role in the prevention and treatment of these diseases. Despite the wide range of available antiplatelet drugs, antiplatelet drug resistance is not rare. So optimizing drug use through personalized treatment strategies to achieve maximum therapeutic benefit remains a major challenge in clinical practice. Non-coding RNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), have made significant progress in understanding their regulatory roles in drug resistance, becoming a frontier area of current research. In addition to the regulatory functions of non-coding RNAs, emerging studies have highlighted the role of RNA modifications, such as N6-methyladenosine (m6A), in the regulation of gene expression and cellular processes involved in antiplatelet drug resistance. These modifications contribute to the stability, splicing, and translation of RNA, further influencing their roles in drug resistance mechanisms. In recent years, significant progress has been made in the research of non-coding RNAs and RNA modifications, revealing their crucial roles in the mechanisms of antiplatelet drug resistance. This review focuses on the latest advancements in non-coding RNA research related to antiplatelet drug resistance and explores the emerging field of RNA modifications. It analyzes potential underlying mechanisms and discusses future research directions, aiming to provide new theoretical support and research perspectives for personalized precision antiplatelet.

Indexed as

antiplatelet drug resistancecardiovascular diseasescerebrovascular diseasenon-coding RNAsRNA modifications

Identifiers

PMID40988928
PMCPMC12450665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.